By Kate Kelland and Ben Hirschler LONDON (Reuters) - Three years after the mysterious MERS virus first emerged in humans, scientists and drugmakers say there is no excuse for not having a vaccine that could have protected those now falling sick and dying in South Korea. The facts behind the coronavirus that causes Middle East Respiratory Syndrome (MERS) have been slow to emerge, partly due to a secretive response in Saudi Arabia, which has suffered an outbreak stretching back to 2012. But scientists do know that it is similar to the deadly SARS virus, that it probably originated in bats, that it is linked to camels, and can pass from person to person. They also understand its molecular structure. That all yields scientific detail for researchers to begin developing a vaccine, and there is clear frustration that work on one has barely begun. The problem is that big pharmaceutical firms are uncertain about the economics of such a vaccine and no governments have yet offered to underwrite a major research effort. "The question is: How long are we going to wait around and just follow these outbreaks before we get serious about making vaccines?" said Adrian Hill, a professor and director at the Jenner Institute at Britain's Oxford University. "There is no sign of MERS going away. It's been around since 2012. And there is really clear evidence now of human-to-human transmission." South Korea said on Monday 150 people there have been infected with MERS in an outbreak started by a businessman returning from the Middle East. Sixteen have died. The vast majority of MERS infections and deaths have been in Saudi Arabia, where more than 1,000 people have been infected since 2012, and some 454 have died. Yet cases of the disease have already been recorded in at least 25 countries, including the United States, China and Britain. MERS, which causes coughing, fever and breathing problems, can lead to pneumonia and kidney failure. Some scientists suspect it has probably crossed other international boundaries undetected, since diagnosing MERS and distinguishing it from other respiratory illnesses that kill elderly or sick people in hospital may not always be possible. MERS infection is caused by a coronavirus from the same family as the one behind Severe Acute Respiratory Syndrome (SARS), which killed around 800 people worldwide in 2002-2003. HIGH DEATH RATE MERS has a much higher death rate - 38 percent versus around 10 percent for SARS, according to World Health Organisation figures - but it also spreads more slowly from person to person, making it less of a threat, for now. "The chances are that South Korea will control it," said Hill. "But should we be taking this risk? No. Should we have made a MERS vaccine? Yes. Could anyone have afforded it? Yes, the government of Saudi Arabia. So should something be done? Yes, someone should go and develop a MERS vaccine sooner rather than later." So far only a handful of small biotechs, including Greffex, Inovio, Novavax, have done any MERS vaccine work and their research is still pre-clinical. Larger drugmakers, however, such as GlaxoSmithKline, are keeping an eye on the situation. "We don't have an active MERS program but we are certainly thinking about what we should do if this becomes an issue," said Ripley Ballou, an infectious diseases expert at GSK who has led the company's Ebola vaccine work. "There is a threat list of diseases that people think are potentially going to do something and MERS is at the top." For profit-orientated drug companies, the problem is working out who is going to use a vaccine, who is going to pay for it and whether this is a commercial market. Many experts, including billionaire philanthropist and champion of global health Bill Gates, now argue there should be a much more structured process whereby governments and companies work together to back early vaccine development work. It is not as if we don't have the scientific know-how. "Viruses are pretty simple organisms and they all have antigens on their surface that are necessary to get them inside cells," said Ballou. "Everybody knows what the target for MERS is, it is the core spike protein, which is one of things that targets the cell receptor and allows it to get in. It's a single protein that can be used to induce an immune response." (Editing by Crispian Balmer)
Christina Bobb's comments on Fox News sounded more like an admission to some of Trump's critics.
- Business Insider
- In The Know by Yahoo
A word to the wise: "Chips and salsa" doesn't mean the same thing everywhere.
The right has used this phrase for others, but doesn't think it should apply to them.
- The Daily Beast
- Chicago Tribune
- The Recount
- USA TODAY
This one may not help the former president's case.
"There's no way Trump wrote that," said "The Daily Show" host.
- Good Housekeeping
- The New York Times
The ads are everywhere — as are the inflated claims: Special shampoos and treatments, sometimes costing thousands of dollars, will make hair grow. But many dermatologists who specialize in hair loss say that most of these products do not work. “There is an endless array of useless hair-growth remedies,” often at “significant cost,” said Dr. Brett King, a dermatologist at Yale School of Medicine. Yet, he added, “because people are desperate, such hair growth remedies continue to abound.” But ther
- ProFootball Talk on NBC Sports
- Ukrayinska Pravda
- The Recount
Fox News’ Steve Doocy explains the real-world consequences of Republicans' FBI-bashing to Sen. Rand Paul (R-KY).
Fox News host Steve Doocey took Senator Rand Paul to task over his accusations that the FBI search was illegitimate, pointing out that the attacks on the agency are putting agents there at risk. DOOCEY: Well, and Senator absolutely Congress has oversight over the FBI and the Department of Justice and everything else. The problem is over the last week or so there's been so much violent rhetoric directed at the FBI and I heard somebody printed FBI stands for Fascist Bureauof Investigation or something like that.
NFL wide receiver Calvin Johnson retired from the league in 2016 after nine seasons playing for the Detroit Lions. Johnson, whose first job was bagging groceries, had a lot to learn about finance when...